A study to improve the care pathways for people, 60 years and over, in South Asia with a broken hip

A cluster randomised controlled trial with embedded process evaluation to investigate the clinical and cost effectiveness of multidisciplinary care in the management of patients with a fracture of the hip

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN23534273

Enrollment

9000

Registered

2024-07-11

Start date

2024-11-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip fracture Injury, Occupational Diseases, Poisoning

Interventions

Hospitals will be randomised to the HIPCARE intervention or usual care, via a centralised computer-based process stratified by country and will be carried out in advance of the start of recruitment.

Eligibility

Sex/Gender

All

Age

60 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients aged 60 years or over having surgery for a hip fracture.

Exclusion criteria

Exclusion criteria: The participant or a carer cannot complete follow-up at 120 days

Design outcomes

Primary

Measure	Time frame
Health-related quality of life measured using EuroQol-5D–5L at baseline and 120 days post-surgery	—

Secondary

Measure	Time frame
1. Mortality, measured using death notification data up to 120 days post-surgery 2. Mobility, measured using the Modified New Mobility Score (mNMS) at baseline and 120 days post-surgery 3. Residential status measured using a bespoke questionnaire at baseline and 120 days post-surgery 4. Complication rate measured using medical records and a bespoke questionnaire at 120 days post-surgery 5. Healthcare and broader resource implications measured using medical records and bespoke questionnaire at baseline and 120 days post-surgery 6. Estimated cost-effectiveness of the trial treatments measured using medical records, bespoke questionnaire, and the Euroqol-5D-5L at 120 days post-surgery	—

Measure

Time frame

1. Mortality, measured using death notification data up to 120 days post-surgery 2. Mobility, measured using the Modified New Mobility Score (mNMS) at baseline and 120 days post-surgery 3. Residential status measured using a bespoke questionnaire at baseline and 120 days post-surgery 4. Complication rate measured using medical records and a bespoke questionnaire at 120 days post-surgery 5. Healthcare and broader resource implications measured using medical records and bespoke questionnaire at baseline and 120 days post-surgery 6. Estimated cost-effectiveness of the trial treatments measured using medical records, bespoke questionnaire, and the Euroqol-5D-5L at 120 days post-surgery

—

Countries

India, Nepal, Philippines, Thailand, Viet Nam

Contacts

Public ContactSumayyah Rashan

hipcare@ndorms.ox.ac.uk+44 (0)1865 223115

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 9, 2026